^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Prostate Cancer

    Related cancers:
    1d
    CDO1 is a new biomarker to discriminate aggressive forms of prostate cancer. (PubMed, Oncogene)
    Altogether, these results describe the loss of CDO1 as a marker of aggressiveness in PCa. Furthermore, the loss of CDO1 is thought to be responsible for tumor progression in vitro by acting on multiple signaling pathways.
    Journal
    |
    CDO1 (Cysteine Dioxygenase Type 1)
    1d
    RNF214 silencing attenuates prostate cancer progression and modulates mTOR signaling through CAV1 ubiquitination. (PubMed, Cell Biosci)
    RNF214 promotes prostate tumor progression by ubiquitinating and targeting CAV1 for degradation, thereby sustaining mTOR signaling. These findings highlight the RNF214-CAV1 axis as a potential therapeutic target in PCa.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • CAV1 (Caveolin 1) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
    1d
    A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT. (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Hoag Memorial Hospital Presbyterian
    New P2 trial
    1d
    β, β-Dimethylacrylshikonin Triggers Caspase-Mediated Cell Apoptosis via Heme Oxygenase-1 Upregulation and ERK/p38 Activation in Prostate Cancer. (PubMed, J Cell Mol Med)
    In conclusion, our results revealed that DMAS induced activation of caspase cascades to elicit cell apoptosis in PC, through HO-1 upregulation and ERK/p38 activation. These findings provide possible avenues for the use of a naturally occurring compound with therapeutic values in fighting prostate carcinogenesis.
    Journal
    |
    HMOX1 (Heme Oxygenase 1) • XIAP (X-Linked Inhibitor Of Apoptosis)
    1d
    Epigenetic and oncogenic inhibitors converge to drive a metabolic catastrophe in castration-resistant prostate cancer. (PubMed, J Clin Invest)
    EZH2 and PI3K pathway inhibitors achieve this by respectively inhibiting two key regulators of metabolism, MYC and HIF-1A, while concomitantly derepressing a pro-apoptotic stress sensor. Together, these studies reveal a promising therapeutic strategy for CRPC and demonstrate how metabolic plasticity can be fatally impaired by co-targeting upstream oncogenic nodes that converge on this important process.
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
    1d
    Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, University of Southern California | N=103 --> 70 | Trial completion date: Nov 2026 --> Dec 2030 | Trial primary completion date: Nov 2025 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • sEphB4-HSA
    1d
    QLF4113 in Participants With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=140, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1 trial
    1d
    Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial (clinicaltrials.gov)
    P=N/A, N=800, Not yet recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Nov 2029 --> Mar 2030 | Initiation date: May 2026 --> Sep 2026 | Trial primary completion date: Nov 2029 --> Mar 2030
    Trial completion date • Trial initiation date • Trial primary completion date
    1d
    A Study of Lower Dose Radiation Therapy for People With Prostate Cancer (clinicaltrials.gov)
    P2, N=54, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    1d
    MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT) (clinicaltrials.gov)
    P=N/A, N=48, Not yet recruiting, Odense University Hospital
    New trial
    1d
    Biopsy29: Combining High-frequency Micro-ultrasound and Multiparametric MRI Target Biopsy for Detecting Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=400, Recruiting, Salzburger Landeskliniken | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Nov 2025 --> Nov 2027
    Trial completion date • Trial primary completion date
    2d
    Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting
    Enrollment closed • Adverse events